Pacira Q2 revenue slightly beats estimates; cuts FY outlook

• Pacira sees 2026 total revenue of $735 mln to $760 mln, down from prior $745 mln to $770 mln
• Company expects 2026 EXPAREL net product sales of $600 mln to $620 mln
• Pacira forecasts 2026 non-GAAP gross margin of 77% to 79%

• US non-opioid pain therapies maker's Q2 revenue rose 6%, slightly beating analyst expectations
• Adjusted net income and adjusted EBITDA for Q2 both beat analyst estimates
• Company completed divestiture of iovera° business to Zimmer Biomet in July

*Applies to a deviation of less than 1%; not applicable for per-share numbers.